CEOs respect importance of reputation

Share this article:
Healthcare CEOs are concerned about corporate reputation, according to a survey by FischerHealth, Porter Novelli Consulting and PRSA Health Academy.

Nearly two-thirds of the 30 CEOs surveyed said reputation was “critical” or “very important” to their organization's success, and similar numbers said a positive shift in reputation “significantly” or “dramatically” affects their bottom line.

A large majority (86%) said negative events would adversely impact their bottom line.

All rated their firm's reputation as “excellent” to “good” with key external audiences, including consumers, regulators, legislators and employees, though less than half (47%) rated their reputation with news media as “very good.”

However, more than one-third (39%) had not measured their reputation. Three-quarters of respondents said they were “satisfied” or “very satisfied” with their staff's ability to understand and deliver on reputation-management objectives.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...